1
|
Brown T, Muls A, Pawlyn C, Boyd K, Cruickshank S. The acceptability of using wearable electronic devices to monitor physical activity of patients with Multiple Myeloma undergoing treatment: a systematic review. Clin Hematol Int 2024; 6:38-53. [PMID: 39268172 PMCID: PMC11391912 DOI: 10.46989/001c.121406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2024] [Accepted: 06/07/2024] [Indexed: 09/15/2024] Open
Abstract
Introduction Multiple myeloma (MM) is diagnosed in 6,000 people in the UK yearly. A performance status measure, based on the patients' reported level of physical activity, is used to assess patients' fitness for treatment. This systematic review aims to explore the current evidence for the acceptability of using wearable devices in patients treated for MM to measure physical activity directly. Methods Three databases were searched (MEDLINE, EMBASE and CINAHL) up until 7th September 2023. Prospective studies using wearable devices to monitor physical activity in patients on treatment for MM were included. Bias across the studies was assessed using the CASP tool. Results Nine studies, with 220 patients on treatment for MM, were included. Only two studies had a low risk of bias. Different wearable device brands were used for varying lengths of time and were worn on either the wrist, upper arm, or chest. Adherence, reported in seven studies, ranged from 50% to 90%. Six studies reported an adherence greater than 75%. Although physical activity was also measured in a heterogenous manner, most studies reported reduced physical activity during treatment, associated with a higher symptom burden. Conclusion Monitoring patients receiving treatment for MM with a wearable device appears acceptable as an objective measure to evaluate physical activity. Due to the heterogeneity of the methods used, the generalisability of the results is limited. Future studies should explore the data collected prospectively and their ability to predict relevant clinical outcomes.
Collapse
Affiliation(s)
- Tommy Brown
- Haematology Research Royal Marsden NHS Foundation Trust
| | - Ann Muls
- Royal Marsden NHS Foundation Trust
| | | | | | | |
Collapse
|
2
|
Avey S, Chatterjee M, Manyakov NV, Cooper P, Sabins N, Mosca K, Mori S, Baribaud F, Morris M, Lehar J, Deiteren A, Cossu M, Smets S, Huizer T, Lamousé‐Smith E, Campbell K, Pandis I. Using a wearable patch to develop a digital monitoring biomarker of inflammation in response to LPS challenge. Clin Transl Sci 2024; 17:e13734. [PMID: 38380580 PMCID: PMC10880037 DOI: 10.1111/cts.13734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2023] [Revised: 01/13/2024] [Accepted: 01/17/2024] [Indexed: 02/22/2024] Open
Abstract
Remote inflammation monitoring with digital health technologies (DHTs) would provide valuable information for both clinical research and care. Controlled perturbations of the immune system may reveal physiological signatures which could be used to develop a digital biomarker of inflammatory state. In this study, molecular and physiological profiling was performed following an in vivo lipopolysaccharide (LPS) challenge to develop a digital biomarker of inflammation. Ten healthy volunteers received an intravenous LPS challenge and were monitored for 24 h using the VitalConnect VitalPatch (VitalPatch). VitalPatch measurements included heart rate (HR), heart rate variability (HRV), respiratory rate (RR), and skin temperature (TEMP). Conventional episodic inpatient vital signs and serum proteins were measured pre- and post-LPS challenge. The VitalPatch provided vital signs that were comparable to conventional methods for assessing HR, RR, and TEMP. A pronounced increase was observed in HR, RR, and TEMP as well as a decrease in HRV 1-4 h post-LPS challenge. The ordering of participants by magnitude of inflammatory cytokine response 2 h post-LPS challenge was consistent with ordering of participants by change from baseline in vital signs when measured by VitalPatch (r = 0.73) but not when measured by conventional methods (r = -0.04). A machine learning model trained on VitalPatch data predicted change from baseline in inflammatory protein response (R2 = 0.67). DHTs, such as VitalPatch, can improve upon existing episodic measurements of vital signs by enabling continuous sensing and have the potential for future use as tools to remotely monitor inflammation.
Collapse
Affiliation(s)
- Stefan Avey
- Janssen Pharmaceutical Research and DevelopmentSpring HousePennsylvaniaUSA
| | | | | | - Philip Cooper
- Janssen Pharmaceutical Research and DevelopmentSpring HousePennsylvaniaUSA
| | - Nina Sabins
- Janssen Pharmaceutical Research and DevelopmentSpring HousePennsylvaniaUSA
| | - Kenneth Mosca
- Janssen Pharmaceutical Research and DevelopmentSpring HousePennsylvaniaUSA
| | - Simone Mori
- Janssen Pharmaceutical Research and DevelopmentSpring HousePennsylvaniaUSA
| | - Frédéric Baribaud
- Janssen Pharmaceutical Research and DevelopmentSpring HousePennsylvaniaUSA
| | - Mark Morris
- Janssen Pharmaceutical Research and DevelopmentSpring HousePennsylvaniaUSA
| | - Joseph Lehar
- Janssen Pharmaceutical Research and DevelopmentSpring HousePennsylvaniaUSA
| | | | - Marta Cossu
- Janssen Pharmaceutical Research and DevelopmentLeidenThe Netherlands
| | - Sophie Smets
- Janssen Pharmaceutical Research and DevelopmentMerksemBelgium
| | - Tanja Huizer
- Janssen Pharmaceutical Research and DevelopmentLeidenThe Netherlands
| | - Esi Lamousé‐Smith
- Janssen Pharmaceutical Research and DevelopmentSpring HousePennsylvaniaUSA
| | - Kim Campbell
- Janssen Pharmaceutical Research and DevelopmentSpring HousePennsylvaniaUSA
| | | |
Collapse
|
3
|
Chen C, Ding S, Wang J. Digital health for aging populations. Nat Med 2023; 29:1623-1630. [PMID: 37464029 DOI: 10.1038/s41591-023-02391-8] [Citation(s) in RCA: 52] [Impact Index Per Article: 52.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Accepted: 05/09/2023] [Indexed: 07/20/2023]
Abstract
Growing life expectancy poses important societal challenges, placing an increasing burden on ever more strained health systems. Digital technologies offer tremendous potential for shifting from traditional medical routines to remote medicine and transforming our ability to manage health and independence in aging populations. In this Perspective, we summarize the current progress toward, and challenges and future opportunities of, harnessing digital technologies for effective geriatric care. Special attention is given to the role of wearables in assisting older adults to monitor their health and maintain independence at home. Challenges to the widespread future use of digital technologies in this population will be discussed, along with a vision for how such technologies will shape the future of healthy aging.
Collapse
Affiliation(s)
- Chuanrui Chen
- Department of Nanoengineering, University of California San Diego, La Jolla, CA, USA
| | - Shichao Ding
- Department of Nanoengineering, University of California San Diego, La Jolla, CA, USA
| | - Joseph Wang
- Department of Nanoengineering, University of California San Diego, La Jolla, CA, USA.
| |
Collapse
|
4
|
Clancy DD, Revette AC, Bahl NE, Ho KT, Manor B, Testa MA, Dieli-Conwright CM, Hshieh T, Driver JA, Abel GA, DuMontier C. Benefits and Barriers of Technology for Home Function and Mobility Assessment: Perspectives of Older Patients With Blood Cancers, Caregivers, and Clinicians. JCO Clin Cancer Inform 2023; 7:e2200171. [PMID: 37098230 PMCID: PMC10281405 DOI: 10.1200/cci.22.00171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2022] [Revised: 02/15/2023] [Accepted: 03/07/2023] [Indexed: 04/27/2023] Open
Abstract
PURPOSE Advances in digital health technology can overcome barriers to measurement of function and mobility for older adults with blood cancers, but little is known about how older adults perceive such technology for use in their homes. METHODS To characterize potential benefits and barriers associated with using technology for home functional assessment, we conducted three semistructured focus groups (FGs) in January 2022. Eligible patients came from the Older Adult Hematologic Malignancies Program at Dana-Farber Cancer Institute (DFCI), which includes adults 73 years and older enrolled during their initial consult with their oncologist. Eligible caregivers were 18 years and older and identified by enrolled patients as their primary caregiver. Eligible clinicians were practicing DFCI hematologic oncologists, nurse practitioners, or physician assistants with ≥2 years of clinical experience. A qualitative researcher led thematic analysis of FG transcripts to identify key themes. RESULTS Twenty-three participants attended the three FGs: eight patients, seven caregivers, and eight oncology clinicians. All participants valued function and mobility assessments and felt that technology could overcome barriers to their measurement. We identified three themes related to potential benefits: making it easier for oncology teams to consider function and mobility; providing standardized, objective data; and facilitating longitudinal data. We also identified four themes related to barriers to home functional assessment: concerns related to privacy and confidentiality, burden of measuring additional patient data, challenges in operating new technology, and concerns related to data improving care. CONCLUSION These data suggest that specific concerns raised by older patients, caregivers, and oncology clinicians must be addressed to improve acceptability and uptake of technology used to measure function and mobility in the home.
Collapse
Affiliation(s)
| | - Anna C. Revette
- Survey and Data Management Core, Dana-Farber Cancer Institute, Boston, MA
- Harvard School of Public Health, Boston, MA
| | | | | | - Bradley Manor
- Harvard Medical School, Boston, MA
- Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA
| | | | | | - Tammy Hshieh
- Dana-Farber Cancer Institute, Boston, MA
- Harvard Medical School, Boston, MA
- Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA
- Brigham and Women's Hospital, Boston, MA
| | - Jane A. Driver
- Harvard School of Public Health, Boston, MA
- Brigham and Women's Hospital, Boston, MA
- Geriatric Research, Education and Clinical Center and Geriatrics and Extended Care, VA Boston Healthcare System, Boston, MA
| | - Gregory A. Abel
- Dana-Farber Cancer Institute, Boston, MA
- Brigham and Women's Hospital, Boston, MA
- Center for Bioethics, Harvard Medical School, Boston, MA
| | - Clark DuMontier
- Dana-Farber Cancer Institute, Boston, MA
- Harvard Medical School, Boston, MA
- Brigham and Women's Hospital, Boston, MA
- Geriatric Research, Education and Clinical Center and Geriatrics and Extended Care, VA Boston Healthcare System, Boston, MA
| |
Collapse
|
5
|
Tonino RPB, Tweardy M, Wegerich S, Brouwer R, Zwaginga JJ, Schipperus MR. Remote Monitoring of Vital and Activity Parameters in Chronic Transfusion-Dependent Patients: A Feasibility Pilot Using Wearable Biosensors. Digit Biomark 2022; 6:117-126. [PMID: 36466954 PMCID: PMC9710428 DOI: 10.1159/000526438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Accepted: 07/06/2022] [Indexed: 09/10/2024] Open
Abstract
Introduction Little is known if, and to what extent, outpatient red blood cell (RBC) transfusions benefit chronic transfusion-dependent patients. Costs, labour, and potential side effects of RBC transfusions cause a restrictive transfusion strategy to be the standard of care. However, effects on the actual performance and quality of life of patients who require RBCs on a regular basis are hardly studied. The aim of this study was to assess if new technologies and techniques like wearable biosensor devices and web-based testing can be used to measure physiological changes, functional activity, and hence eventually better assess quality of life in a cohort of transfusion-dependent patients. Methods We monitored 5 patients who regularly receive transfusions during one transfusion cycle with the accelerateIQ biosensor platform, the Withings Steel HR, and web-based cognitive and quality of life testing. Results Data collection by the deployed devices was shown to be feasible; the AccelerateIQ platform rendered data of which 97.8% was of high quality and usable; of the data the Withings Steel HR rendered, 98.9% was of high quality and usable. Furthermore, heart rate decreased and cognition improved significantly following RBC transfusions. Activity and quality of life measures did not show transfusion-induced changes. Conclusion In a 5-patient cohort of transfusion-dependent patients, we found that the accelerateIQ, Withings Steel HR, and CANTAB platforms enable acquisition of high-quality data. The collected data suggest that RBC transfusions significantly and reversibly decrease heart rate and increase sustained attention in this cohort. This feasibility study justifies larger validation trials to confirm that these wearables can indeed help to determine personalized RBC transfusion strategies and thus optimization of each patient's quality of life.
Collapse
Affiliation(s)
- Rik Paulus Bernardus Tonino
- Research, TRIP, Leiden, The Netherlands
- Hematology, HagaZiekenhuis, The Hague, The Netherlands
- Hematology, LUMC, Leiden, The Netherlands
| | | | | | - Rolf Brouwer
- Hematology, Reinier de Graaf Gasthuis, Delft, The Netherlands
| | - Jaap Jan Zwaginga
- Research, TRIP, Leiden, The Netherlands
- Hematology, LUMC, Leiden, The Netherlands
- CTR, Sanquin, Amsterdam, The Netherlands
| | - Martin Roelof Schipperus
- Research, TRIP, Leiden, The Netherlands
- Hematology, HagaZiekenhuis, The Hague, The Netherlands
- CTR, Sanquin, Amsterdam, The Netherlands
| |
Collapse
|
6
|
Randine P, Sharma A, Hartvigsen G, Johansen HD, Årsand E. Information and Communication Technology-based Interventions for Chronic Diseases Consultation: Scoping Review. Int J Med Inform 2022; 163:104784. [DOI: 10.1016/j.ijmedinf.2022.104784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Revised: 04/08/2022] [Accepted: 04/24/2022] [Indexed: 11/15/2022]
|
7
|
Jacobsen M, Rottmann P, Dembek TA, Gerke AL, Gholamipoor R, Blum C, Hartmann NU, Verket M, Kaivers J, Jäger P, Baermann BN, Heinemann L, Marx N, Müller-Wieland D, Kollmann M, Seyfarth M, Kobbe G. Feasibility of Wearable-Based Remote Monitoring in Patients During Intensive Treatment for Aggressive Hematologic Malignancies. JCO Clin Cancer Inform 2022; 6:e2100126. [PMID: 35025669 DOI: 10.1200/cci.21.00126] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
PURPOSE Intensive treatment protocols for aggressive hematologic malignancies harbor a high risk of serious clinical complications, such as infections. Current techniques of monitoring vital signs to detect such complications are cumbersome and often fail to diagnose them early. Continuous monitoring of vital signs and physical activity by means of an upper arm medical wearable allowing 24/7 streaming of such parameters may be a promising alternative. METHODS This single-arm, single-center observational trial evaluated symptom-related patient-reported outcomes and feasibility of a wearable-based remote patient monitoring. All wearable data were reviewed retrospectively and were not available to the patient or clinical staff. A total of 79 patients (54 inpatients and 25 outpatients) participated and received standard-of-care treatment for a hematologic malignancy. In addition, the wearable was continuously worn and self-managed by the patient to record multiple parameters such as heart rate, oxygen saturation, and physical activity. RESULTS Fifty-one patients (94.4%) in the inpatient cohort and 16 (64.0%) in the outpatient cohort reported gastrointestinal symptoms (diarrhea, nausea, and emesis), pain, dyspnea, or shivering in at least one visit. With the wearable, vital signs and physical activity were recorded for a total of 1,304.8 days. Recordings accounted for 78.0% (63.0-88.5; median [interquartile range]) of the potential recording time for the inpatient cohort and 84.6% (76.3-90.2) for the outpatient cohort. Adherence to the wearable was comparable in both cohorts, but decreased moderately over time during the trial. CONCLUSION A high adherence to the wearable was observed in patients on intensive treatment protocols for a hematologic malignancy who experience high symptom burden. Remote patient monitoring of vital signs and physical activity was demonstrated to be feasible and of primarily sufficient quality.
Collapse
Affiliation(s)
- Malte Jacobsen
- Faculty of Health, University Witten/Herdecke, Witten, Germany.,Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany
| | - Pauline Rottmann
- Department of Hematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.,Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Till A Dembek
- Department of Neurology, Faculty of Medicine, University of Cologne, Cologne, Germany
| | - Anna L Gerke
- Department of Hematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.,Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Rahil Gholamipoor
- Department of Computer Science, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Christopher Blum
- Department of Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Niels-Ulrik Hartmann
- Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany
| | - Marlo Verket
- Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany
| | - Jennifer Kaivers
- Department of Hematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.,Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Paul Jäger
- Department of Hematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.,Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Ben-Niklas Baermann
- Department of Hematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.,Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | | | - Nikolaus Marx
- Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany
| | - Dirk Müller-Wieland
- Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany
| | - Markus Kollmann
- Department of Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Melchior Seyfarth
- Faculty of Health, University Witten/Herdecke, Witten, Germany.,Department of Cardiology, Helios University Hospital of Wuppertal, Wuppertal, Germany
| | - Guido Kobbe
- Department of Hematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.,Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| |
Collapse
|
8
|
Rajbhandary PL, Nallathambi G, Selvaraj N, Tran T, Colliou O. ECG Signal Quality Assessments of a Small Bipolar Single-Lead Wearable Patch Sensor. Cardiovasc Eng Technol 2022; 13:783-796. [PMID: 35292914 PMCID: PMC8923108 DOI: 10.1007/s13239-022-00617-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Accepted: 02/23/2022] [Indexed: 01/27/2023]
Abstract
PURPOSE There is an increasing clinical interest in the adoption of small single-lead wearable ECG sensors for continuous cardiac monitoring. The purpose of this work is to assess ECG signal quality of such devices compared to gold standard 12-lead ECG. METHODS The ECG signal from a 1-lead patch was systematically compared to the 12-lead ECG device in thirty subjects to establish its diagnostic accuracy in terms of clinically relevant signal morphology, wave representation, fiducial markers and interval and wave duration. One minute ECG segments with good signal quality was selected for analysis and the features of ECG were manually annotated for comparative assessment. RESULTS The patch showed closest similarity based on correlation and normalized root-mean-square error to the standard ECG leads I, II, [Formula: see text] and [Formula: see text]. P-wave and QRS complexes in the patch showed sensitivity (Se) and positive predictive value (PPV) of at least 99.8% compared to lead II. T-wave representation showed Se and PPV of at least 99.9% compared to lead [Formula: see text] and [Formula: see text]. Mean errors for onset and offset of the ECG waves, wave durations, and ECG intervals were within 2 samples based on 125Hz patch ECG sampling frequency. CONCLUSION This study demonstrates the diagnostic capability with similar morphological representation and reasonable timing accuracy of ECG signal from a patch sensor compared to 12-lead ECG. The advantages and limitations of small bipolar single-lead wearable patch sensor compared to 12-lead ECG are discussed in the context of relevant differences in ECG signal for clinical applications.
Collapse
|
9
|
Jagannath S, Mikhael J, Nadeem O, Raje N. Digital Health for Patients With Multiple Myeloma: An Unmet Need. JCO Clin Cancer Inform 2021; 5:1096-1105. [PMID: 34735265 DOI: 10.1200/cci.20.00145] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Multiple myeloma (MM) is associated with the highest symptom burden and lowest health-related quality of life (HRQoL) among patients with hematologic malignancies. HRQoL in MM is heterogeneous, varying over the course of disease, with the highest burden at diagnosis and relapse. Patients with MM are increasingly being treated with oral maintenance medications at home. As a result, longitudinal monitoring of medication adherence and patient-reported outcomes, including HRQoL, could inform on disease status, therapeutic tolerability, and satisfaction with care. Digital health technologies, including telemedicine, mobile health, and wearable devices, are poised to become an integral part of modern health care, in part due to the surge in telemedicine necessitated by the COVID-19 pandemic. Although the literature has many reports on the use of digital health technologies in other types of cancers, fewer studies report on their application to MM. In the current narrative review, we survey the applications of digital health for MM. Although there is evidence that some are associated with improved health outcomes, challenges exist that must be met to ensure more widespread adoption. These include the need for increased awareness by patients and health care providers, lack of access by the typical older patient with MM, absence of randomized clinical trials, and low integration with current workflows such as electronic health records. Following our summary of technologies that could benefit patients with MM, we end by describing our vision for how they can be integrated into each phase of the patient journey.
Collapse
Affiliation(s)
| | - Joseph Mikhael
- Translational Genomics Research Institute (TGen), City of Hope Cancer Center, Phoenix, AZ
| | - Omar Nadeem
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - Noopur Raje
- Center for Multiple Myeloma, Massachusetts General Hospital, Harvard Medical School, Boston, MA
| |
Collapse
|
10
|
Morgado Areia C, Santos M, Vollam S, Pimentel M, Young L, Roman C, Ede J, Piper P, King E, Gustafson O, Harford M, Shah A, Tarassenko L, Watkinson P. A Chest Patch for Continuous Vital Sign Monitoring: Clinical Validation Study During Movement and Controlled Hypoxia. J Med Internet Res 2021; 23:e27547. [PMID: 34524087 PMCID: PMC8482195 DOI: 10.2196/27547] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 04/15/2021] [Accepted: 06/21/2021] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND The standard of care in general wards includes periodic manual measurements, with the data entered into track-and-trigger charts, either on paper or electronically. Wearable devices may support health care staff, improve patient safety, and promote early deterioration detection in the interval between periodic measurements. However, regulatory standards for ambulatory cardiac monitors estimating heart rate (HR) and respiratory rate (RR) do not specify performance criteria during patient movement or clinical conditions in which the patient's oxygen saturation varies. Therefore, further validation is required before clinical implementation and deployment of any wearable system that provides continuous vital sign measurements. OBJECTIVE The objective of this study is to determine the agreement between a chest-worn patch (VitalPatch) and a gold standard reference device for HR and RR measurements during movement and gradual desaturation (modeling a hypoxic episode) in a controlled environment. METHODS After the VitalPatch and gold standard devices (Philips MX450) were applied, participants performed different movements in seven consecutive stages: at rest, sit-to-stand, tapping, rubbing, drinking, turning pages, and using a tablet. Hypoxia was then induced, and the participants' oxygen saturation gradually reduced to 80% in a controlled environment. The primary outcome measure was accuracy, defined as the mean absolute error (MAE) of the VitalPatch estimates when compared with HR and RR gold standards (3-lead electrocardiography and capnography, respectively). We defined these as clinically acceptable if the rates were within 5 beats per minute for HR and 3 respirations per minute (rpm) for RR. RESULTS Complete data sets were acquired for 29 participants. In the movement phase, the HR estimates were within prespecified limits for all movements. For RR, estimates were also within the acceptable range, with the exception of the sit-to-stand and turning page movements, showing an MAE of 3.05 (95% CI 2.48-3.58) rpm and 3.45 (95% CI 2.71-4.11) rpm, respectively. For the hypoxia phase, both HR and RR estimates were within limits, with an overall MAE of 0.72 (95% CI 0.66-0.78) beats per minute and 1.89 (95% CI 1.75-2.03) rpm, respectively. There were no significant differences in the accuracy of HR and RR estimations between normoxia (≥90%), mild (89.9%-85%), and severe hypoxia (<85%). CONCLUSIONS The VitalPatch was highly accurate throughout both the movement and hypoxia phases of the study, except for RR estimation during the two types of movements. This study demonstrated that VitalPatch can be safely tested in clinical environments to support earlier detection of cardiorespiratory deterioration. TRIAL REGISTRATION ISRCTN Registry ISRCTN61535692; https://www.isrctn.com/ISRCTN61535692.
Collapse
Affiliation(s)
- Carlos Morgado Areia
- Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
- National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom
| | - Mauro Santos
- National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom
- Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, United Kingdom
| | - Sarah Vollam
- Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
- National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom
| | - Marco Pimentel
- National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom
- Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, United Kingdom
| | - Louise Young
- Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
- National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom
| | - Cristian Roman
- National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom
- Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, United Kingdom
| | - Jody Ede
- Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
- National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom
| | - Philippa Piper
- Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
| | - Elizabeth King
- Therapies Clinical Service Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
| | - Owen Gustafson
- Therapies Clinical Service Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
| | - Mirae Harford
- Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
- National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom
| | - Akshay Shah
- Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Lionel Tarassenko
- National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom
- Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, United Kingdom
| | - Peter Watkinson
- Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
- National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom
- Kadoorie Centre for Critical Care Research and Education, Oxford University Hospitals NHS Trust, Oxford, United Kingdom
| |
Collapse
|
11
|
Channa A, Popescu N, Skibinska J, Burget R. The Rise of Wearable Devices during the COVID-19 Pandemic: A Systematic Review. SENSORS (BASEL, SWITZERLAND) 2021; 21:5787. [PMID: 34502679 PMCID: PMC8434481 DOI: 10.3390/s21175787] [Citation(s) in RCA: 57] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 07/21/2021] [Accepted: 08/24/2021] [Indexed: 12/16/2022]
Abstract
The COVID-19 pandemic has wreaked havoc globally and still persists even after a year of its initial outbreak. Several reasons can be considered: people are in close contact with each other, i.e., at a short range (1 m), and the healthcare system is not sufficiently developed or does not have enough facilities to manage and fight the pandemic, even in developed countries such as the USA and the U.K. and countries in Europe. There is a great need in healthcare for remote monitoring of COVID-19 symptoms. In the past year, a number of IoT-based devices and wearables have been introduced by researchers, providing good results in terms of high accuracy in diagnosing patients in the prodromal phase and in monitoring the symptoms of patients, i.e., respiratory rate, heart rate, temperature, etc. In this systematic review, we analyzed these wearables and their need in the healthcare system. The research was conducted using three databases: IEEE Xplore®, Web of Science®, and PubMed Central®, between December 2019 and June 2021. This article was based on the PRISMA guidelines. Initially, 1100 articles were identified while searching the scientific literature regarding this topic. After screening, ultimately, 70 articles were fully evaluated and included in this review. These articles were divided into two categories. The first one belongs to the on-body sensors (wearables), their types and positions, and the use of AI technology with ehealth wearables in different scenarios from screening to contact tracing. In the second category, we discuss the problems and solutions with respect to utilizing these wearables globally. This systematic review provides an extensive overview of wearable systems for the remote management and automated assessment of COVID-19, taking into account the reliability and acceptability of the implemented technologies.
Collapse
Affiliation(s)
- Asma Channa
- Computer Science Department, University POLITEHNICA of Bucharest, RO-060042 Bucharest, Romania
- DIIES Department, University Mediterranea of Reggio Calabria, 89100 Reggio Calabria, Italy
| | - Nirvana Popescu
- Computer Science Department, University POLITEHNICA of Bucharest, RO-060042 Bucharest, Romania
| | - Justyna Skibinska
- Department of Telecommunications, Brno University of Technology, 61600 Brno, Czech Republic; (J.S.); (R.B.)
- Unit of Electrical Engineering, Tampere University, 33720 Tampere, Finland
| | - Radim Burget
- Department of Telecommunications, Brno University of Technology, 61600 Brno, Czech Republic; (J.S.); (R.B.)
| |
Collapse
|
12
|
Kareem M, Lei N, Ali A, Ciaccio EJ, Acharya UR, Faust O. A review of patient-led data acquisition for atrial fibrillation detection to prevent stroke. Biomed Signal Process Control 2021. [DOI: 10.1016/j.bspc.2021.102818] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
Ding X, Clifton D, Ji N, Lovell NH, Bonato P, Chen W, Yu X, Xue Z, Xiang T, Long X, Xu K, Jiang X, Wang Q, Yin B, Feng G, Zhang YT. Wearable Sensing and Telehealth Technology with Potential Applications in the Coronavirus Pandemic. IEEE Rev Biomed Eng 2021; 14:48-70. [PMID: 32396101 DOI: 10.1109/rbme.2020.2992838] [Citation(s) in RCA: 103] [Impact Index Per Article: 34.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Coronavirus disease 2019 (COVID-19) has emerged as a pandemic with serious clinical manifestations including death. A pandemic at the large-scale like COVID-19 places extraordinary demands on the world's health systems, dramatically devastates vulnerable populations, and critically threatens the global communities in an unprecedented way. While tremendous efforts at the frontline are placed on detecting the virus, providing treatments and developing vaccines, it is also critically important to examine the technologies and systems for tackling disease emergence, arresting its spread and especially the strategy for diseases prevention. The objective of this article is to review enabling technologies and systems with various application scenarios for handling the COVID-19 crisis. The article will focus specifically on 1) wearable devices suitable for monitoring the populations at risk and those in quarantine, both for evaluating the health status of caregivers and management personnel, and for facilitating triage processes for admission to hospitals; 2) unobtrusive sensing systems for detecting the disease and for monitoring patients with relatively mild symptoms whose clinical situation could suddenly worsen in improvised hospitals; and 3) telehealth technologies for the remote monitoring and diagnosis of COVID-19 and related diseases. Finally, further challenges and opportunities for future directions of development are highlighted.
Collapse
|
14
|
Point of care TECHNOLOGIES. Digit Health 2021. [DOI: 10.1016/b978-0-12-818914-6.00008-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
15
|
Areia C, Young L, Vollam S, Ede J, Santos M, Tarassenko L, Watkinson P. Wearability Testing of Ambulatory Vital Sign Monitoring Devices: Prospective Observational Cohort Study. JMIR Mhealth Uhealth 2020; 8:e20214. [PMID: 33325827 PMCID: PMC7773507 DOI: 10.2196/20214] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 08/28/2020] [Accepted: 10/21/2020] [Indexed: 12/16/2022] Open
Abstract
Background Timely recognition of patient deterioration remains challenging. Ambulatory monitoring systems (AMSs) may provide support to current monitoring practices; however, they need to be thoroughly tested before implementation in the clinical environment for early detection of deterioration. Objective The objective of this study was to assess the wearability of a selection of commercially available AMSs to inform a future prospective study of ambulatory vital sign monitors in an acute hospital ward. Methods Five pulse oximeters (4 with finger probes and 1 wrist-worn only, collecting pulse rates and oxygen saturation) and 2 chest patches (collecting heart rates and respiratory rates) were selected to be part of this study: The 2 chest-worn patches were VitalPatch (VitalConnect) and Peerbridge Cor (Peerbridge); the 4 wrist-worn devices with finger probe were Nonin WristOx2 3150 (Nonin), Checkme O2+ (Viatom Technology), PC-68B, and AP-20 (both from Creative Medical); and the 1 solely wrist-worn device was Wavelet (Wavelet Health). Adult participants wore each device for up to 72 hours while performing usual “activities of daily living” and were asked to score the perceived exertion and perception of pain or discomfort by using the Borg CR-10 scale; thoughts and feelings caused by the AMS using the Comfort Rating Scale (CRS); and to provide general free text feedback. Median and IQRs were reported and nonparametric tests were used to assess differences between the devices’ CRS scores. Results Quantitative scores and feedback were collected in 70 completed questionnaires from 20 healthy volunteers, with each device tested approximately 10 times. The Wavelet seemed to be the most wearable device (P<.001) with an overall median (IQR) CRS score of 1.00 (0.88). There were no statistically significant differences in wearability between the chest patches in the CRS total score; however, the VitalPatch was superior in the Attachment section (P=.04) with a median (IQR) score of 3.00 (1.00). General pain and discomfort scores and total percentage of time worn are also reflective of this. Conclusions Our results suggest that adult participants prefer to wear wrist-worn pulse oximeters without a probe compressing the fingertip and they prefer to wear a smaller chest patch. A compromise between wearability, reliability, and accuracy should be made for successful and practical integration of AMSs within the hospital environment.
Collapse
Affiliation(s)
- Carlos Areia
- Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.,National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom
| | - Louise Young
- Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.,National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom
| | - Sarah Vollam
- Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.,National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom
| | - Jody Ede
- Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.,National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom
| | - Mauro Santos
- National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom.,Department of Engineering Science, Institute of Biomedical Engineering, University of Oxford, Oxford, United Kingdom
| | - Lionel Tarassenko
- National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom.,Department of Engineering Science, Institute of Biomedical Engineering, University of Oxford, Oxford, United Kingdom
| | - Peter Watkinson
- Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.,National Institute for Health Research, Biomedical Research Centre, Oxford, United Kingdom
| |
Collapse
|
16
|
Breteler MJM, Numan L, Ruurda JP, van Hillegersberg R, van der Horst S, Dohmen DAJ, van Rossum MC, Kalkman CJ. Wireless Remote Home Monitoring of Vital Signs in Patients Discharged Early After Esophagectomy: Observational Feasibility Study. JMIR Perioper Med 2020; 3:e21705. [PMID: 33393923 PMCID: PMC7728408 DOI: 10.2196/21705] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Revised: 07/22/2020] [Accepted: 10/28/2020] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Hospital stays after major surgery are shorter than ever before. Although enhanced recovery and early discharge have many benefits, some complications will now first manifest themselves in home settings. Remote patient monitoring with wearable sensors in the first days after hospital discharge may capture clinical deterioration earlier but is largely uncharted territory. OBJECTIVE This study aimed to assess the technical feasibility of patients, discharged after esophagectomy, being remotely monitored at home with a wireless patch sensor and the experiences of these patients. In addition, we determined whether observing vital signs with a wireless patch sensor influences clinical decision making. METHODS In an observational feasibility study, vital signs of patients were monitored with a wearable patch sensor (VitalPatch, VitalConnect Inc) during the first 7 days at home after esophagectomy and discharge from hospital. Vital signs trends were shared with the surgical team once a day, and they were asked to check the patient's condition by phone each morning. Patient experiences were evaluated with a questionnaire, and technical feasibility was analyzed on a daily basis as the percentage of data loss and gap durations. In addition, the number of patients for whom a change in clinical decision was made based on the results of remote vital signs monitoring at home was assessed. RESULTS Patients (N=20) completed 7 days each of home monitoring with the wearable patch sensor. Each of the patients had good recovery at home, and remotely observed vital signs trends did not alter clinical decision making. Patients appreciated that surgeons checked their vital signs daily (mean 4.4/5) and were happy to be called by the surgical team each day (mean 4.5/5). Wearability of the patch was high (mean 4.4/5), and no reports of skin irritation were mentioned. Overall data loss of vital signs measurements at home was 25%; both data loss and gap duration varied considerably among patients. CONCLUSIONS Remote monitoring of vital signs combined with telephone support from the surgical team was feasible and well perceived by all patients. Future studies need to evaluate the impact of home monitoring on patient outcome as well as the cost-effectiveness of this new approach.
Collapse
Affiliation(s)
- Martine J M Breteler
- Department of Anesthesiology, University Medical Center Utrecht, Utrecht, Netherlands.,Luscii Healthtech BV, Amsterdam, Netherlands
| | - Lieke Numan
- Department of Anesthesiology, University Medical Center Utrecht, Utrecht, Netherlands.,Department of Technical Medicine, University of Twente, Enschede, Netherlands
| | - Jelle P Ruurda
- Department of Surgery, University Medical Center Utrecht, Utrecht, Netherlands
| | | | | | | | - Mathilde C van Rossum
- Department of Technical Medicine, University of Twente, Enschede, Netherlands.,Biomedical Signals and Systems Group, University of Twente, Enschede, Netherlands
| | - Cor J Kalkman
- Department of Anesthesiology, University Medical Center Utrecht, Utrecht, Netherlands
| |
Collapse
|